Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Retained Earnings (2016 - 2025)

Arcadia Biosciences' Retained Earnings history spans 11 years, with the latest figure at -$281.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 0.84% year-over-year to -$281.2 million; the TTM value through Dec 2025 reached -$281.2 million, down 0.84%, while the annual FY2025 figure was -$281.2 million, 0.84% down from the prior year.
  • Retained Earnings reached -$281.2 million in Q4 2025 per RKDA's latest filing, roughly flat from -$279.9 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $161000.0 in Q1 2024 to a low of -$281.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$206.9 million, with a median of -$255.7 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: crashed 1056566.67% in 2022, then soared 100.06% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$226.5 million in 2021, then fell by 13.85% to -$257.9 million in 2022, then soared by 100.04% to $101000.0 in 2023, then tumbled by 276216.83% to -$278.9 million in 2024, then decreased by 0.84% to -$281.2 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Retained Earnings are -$281.2 million (Q4 2025), -$279.9 million (Q3 2025), and -$280.7 million (Q2 2025).